LA JOLLA, CALIFORNIA / August 29, 2023 / GRI Bio, Inc. (NASDAQ: GRI), a clinical-stage biotechnology company developing novel immunotherapies that modulate natural killer T (NKT) cells, today announced it has engaged B2i Digital, Inc. (“B2i”) to execute an innovative digital engagement and awareness program. B2i brings together decades of experience from public relations, investment banking, and digital marketing to advise on and develop marketing campaigns to target appropriate stakeholders.
As part of the targeted campaign, B2i will harness its platform and data-driven digital marketing expertise to highlight GRI Bio's differentiated pipeline of NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
"As we work toward major catalysts, we want our story to reach new and valuable audiences," said GRI Bio CEO Marc Hertz, Ph.D. "B2i Digital's cutting-edge digital technologies will allow us to communicate our progress, competitive advantages, and long-term vision to stakeholders."
"We are proud to partner with GRI Bio as they pioneer novel immunotherapies leveraging NKT cell biology," added David Shapiro, B2i Digital CEO. "From a deep pipeline to an extensive compound library, GRI Bio is delivering on its mission to develop transformative NKT cell-targeted medicines. We look forward to leveraging the full power of our digital toolset to showcase and expand GRI Bio’s stakeholder base and visibility to our 410,000+ social media community."